Monte Rosa Therapeutics (GLUE) Accumulated Depreciation & Amortization (2023 - 2025)
Historic Accumulated Depreciation & Amortization for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $25.5 million.
- Monte Rosa Therapeutics' Accumulated Depreciation & Amortization rose 3944.49% to $25.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.5 million, marking a year-over-year increase of 3944.49%. This contributed to the annual value of $20.4 million for FY2024, which is 6631.82% up from last year.
- Monte Rosa Therapeutics' Accumulated Depreciation & Amortization amounted to $25.5 million in Q3 2025, which was up 3944.49% from $23.4 million recorded in Q2 2025.
- Monte Rosa Therapeutics' 5-year Accumulated Depreciation & Amortization high stood at $25.5 million for Q3 2025, and its period low was $8.6 million during Q2 2023.
- Its 3-year average for Accumulated Depreciation & Amortization is $16.6 million, with a median of $16.2 million in 2024.
- Data for Monte Rosa Therapeutics' Accumulated Depreciation & Amortization shows a peak YoY increase of 8916.39% (in 2024) and a maximum YoY decrease of 1549.33% (in 2024) over the last 5 years.
- Over the past 3 years, Monte Rosa Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $12.2 million in 2023, then skyrocketed by 66.32% to $20.4 million in 2024, then grew by 25.34% to $25.5 million in 2025.
- Its Accumulated Depreciation & Amortization was $25.5 million in Q3 2025, compared to $23.4 million in Q2 2025 and $21.3 million in Q1 2025.